ERAS
$13.37-0.14 (-1.04%)
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Recent News
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share a common thread: analysts see asymmetric upside in names where the market has not yet priced in the full probability of success. uniQure: ... uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration?
In early March 2026, Tango Therapeutics and Erasca announced a clinical trial collaboration and supply agreement to test Erasca’s pan-RAS molecular glue ERAS-0015 with Tango’s PRMT5 inhibitor vopimetostat in MTAP-deleted pancreatic and RAS-mutant non-small cell lung cancer. The combination seeks to exploit the dependency created by co-occurring MTAP deletions and RAS mutations, aiming for a dual-targeted approach that could more effectively shut down RAS signaling and PRMT5 activity in...
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
Tango Therapeutics stock hits a record high after signing a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combo in MTAP-deleted RAS-mutant cancers.
Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact
Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca.
Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum
What recent performance suggests about Erasca shares Erasca (ERAS) has caught investor attention after a sharp move in the stock over the past month, with shares closing at US$13.66 and showing very large total returns over the past 3 months. See our latest analysis for Erasca. That recent 30-day share price return of around 30% sits on top of strong year-to-date momentum, and the very large one year total shareholder return suggests sentiment around Erasca’s pipeline has shifted...